A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer

Table 3

Reasons for discontinuation of treatment with oxaliplatin.

Reason	Number (%) patients
Completed the prescribed regimen	90 (46)
Disease relapse/recurrence	31 (16)
Adverse events	24 (12)
Death	12 (6)
Patient withdrew consent	3 (2)
Patient withdrew treatment consent only	10 (5)
Physician’s decision to discontinue treatment	13 (7)
Other	12 (6)

The percentage is calculated out of 195, the total number of patients in the survey’s cohort.